Saccharomyces boulardii and Reduced Symptom Severity

Doses used in studies

mg/day: 600–1,000 (median 800, IQR 700–900) — 2 studies

Time to effect

Median: 3.1 weeks · IQR 2.1 weeks–4 weeks · Range 8 days–5 weeks — Reported in 2 of 2 studies

Safety in these studies

Overall tolerabilityReported
Treatment with Sb on acute inflammatory diarrhoea of viral aetiology shows no changes regarding the severity of the symptoms; nevertheless, it seems to impact improvement positively.
from: Effectiveness of Saccharomyces Boulardii CNCM I-745 probiotic in acute inflammatory viral

2 of 2 papers

Effectiveness of Saccharomyces Boulardii CNCM I-745 probiotic in acute inflammatory viral diarrhoea in adults: results from a single-centre randomized trial.
- 2023-07-03
- RCT · n = 46
- BMC gastroenterology 23(1)
- - Marcela Ag Salazar-Parra
  - Roberto U Cruz-Neri
  - Xóchitl Ar Trujillo-Trujillo
  - Juan J Dominguez-Mora
  - Héctor I Cruz-Neri
  - Jazmín M Guzmán-Díaz
  - Mario J Guzmán-Ruvalcaba
  - Jesús O Vega-Gastelum
  - Kriscia V Ascencio-Díaz
  - Maria F Zarate-Casas
  - Fanny Y González-Ponce
  - Francisco J Barbosa-Camacho
  - Clotilde Fuentes-Orozco
  - Gabino Cervantes-Guevara
  - Enrique Cervantes-Pérez
  - Guillermo Alonso Cervantes-Cardona
  - Ana Olivia Cortés-Flores
  - Alejandro González-Ojeda
- PubMed: 37400812
- DOI: 10.1186/s12876-023-02863-8
2 Insights on
- Reduced Symptom Severity
- High evidence
- Clinical
Treatment with Sb on acute inflammatory diarrhoea of viral aetiology shows no changes regarding the severity of the symptoms
Effect
Neutral
Effect size
Small
Significant
No
Dose
600 mg/day
[Study on the efficacy of combination therapy with rifaximin and Saccharomyces boulardii CNCM I-745 in patients with small intestinal bacterial overgrowth associated with long-term use of proton pump inhibitors].
- 2025-08-28
- RCT · n = 108
- Terapevticheskii arkhiv 97(8)
- - I V Maev
  - D N Andreev
  - R I Shaburov
  - A V Zaborovsky
  - A K Fomenko
  - P S Sokolov
  - S V Tsaregorodtsev
  - M K Devkota
  - D T Dicheva
  - S V Cheremushkin
  - N V Cheremushkinа
  - A V Vychkin
- PubMed: 40884341
- DOI: 10.26442/00403660.2025.08.203301
7 Insights on
- Reduced Symptom Severity
- High evidence
- Large Human Trial
- Clinical
The final median "7 × 7" Questionnaire score was significantly lower in Group 2 (p = 0.0010)
Effect
Beneficial
Effect size
Small
Significant
Yes
Dose
500 mg twice daily

Saccharomyces boulardii and Reduced Symptom Severity

Effectiveness of Saccharomyces Boulardii CNCM I-745 probiotic in acute inflammatory viral diarrhoea in adults: results from a single-centre randomized trial.

[Study on the efficacy of combination therapy with rifaximin and Saccharomyces boulardii CNCM I-745 in patients with small intestinal bacterial overgrowth associated with long-term use of proton pump inhibitors].